Vimta Labs Limited announced its unaudited financial results for the first quarter ended June 30, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance (₹ Mn)
| Particulars | Q1 FY27 | Q4 FY26 | QoQ(%) | Q1 FY26 | YoY (%) |
| Total Income | 1,129 | 1,120 | 0.8% | 993 | 13.7% |
| EBITDA (including other income) | 411 | 421 | -2.4% | 354 | 16.0% |
| EBITDA Margin | 36.4% | 37.6% | | 35.7% | |
| PAT | 210 | 211 | -0.3% | 189 | 11.4% |
| PAT Margin | 18.6% | 18.9% | | 19.0% | |
| Basic EPS | 4.7 | 4.7 | -0.5% | 4.2 | 11.0% |
Management Commentary
Ms. Harita Vasireddi, Managing Director, commented on the results: "Vimta Labs delivered another strong quarter, with total income of ₹1,129 Mn, up 13.7% YoY. Our Pharmaceutical Research and Testing Services business recorded healthy traction during the quarter. While ongoing global uncertainties continued to impact the Food Testing division, the business is progressively offsetting these headwinds through deeper domestic market penetration and improved traction in local opportunities. The quarter's performance underscores the resilience of our operating model and the strength of our diversified service portfolio."
Operational Highlights
- Successfully completed a regulatory audit from Ukraine during the quarter
- Commenced operations in Biologics contract research and development services (CRADS)
- Management remains optimistic about industry prospects and evolving business opportunities